Gabrielle Lakusta

Gabrielle grew up in the Lower Mainland of B.C. and has lived in Vancouver since 2011. She holds an Associate of Arts Degree from Langara College, and a Bachelors of Arts Major in Journalism from Kwantlen Polytechnic University. Now, she writes for INN focusing on Life Science Investing. Aside from work, Gabrielle enjoys travelling, and enjoying the outdoors—especially when hiking and cycling.

glakusta@resourceinvestingnews.com

Articles

Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study

Mateon Therapeutics (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that the U.S....

August 17th, 2018

Evolus Granted Approval of DWP-450 by Health Canada

Evolus (NASDAQ:EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for...

August 17th, 2018

Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials

Akari Therapeutics (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and...

August 17th, 2018

Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector

Antares Pharma (NASDAQ:ATRS) announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical, epinephrine auto injector drug-device...

August 17th, 2018

Clementia Completes Phase 3 Move Trial Patient Enrolment

Clementia Pharmaceuticals announced on Thursday that it has completed enrolment for the Phase 3 Move trial with palovarotene.

August 16th, 2018

Summit Awarded Additional US$12 Million from BARDA

On Thursday, Summit Therapeutics was awarded an additional US$12 million, bringing its total to US$44 million in gross committed funding...

August 16th, 2018

Evoke Pharma’s Gimoti NDA Accepted for FDA Review

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company’s 505(b)(2)...

August 16th, 2018

Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201

Wave Life Sciences (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced...

August 16th, 2018

Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection

Summit Therapeutics (NASDAQ:SMMT, AIM:SUMM), a leader in antibiotic innovation, today announces that it has been awarded an additional $12 million...

August 16th, 2018

Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP

Clementia Pharmaceuticals (NASDAQ:CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other diseases, today announced the...

August 16th, 2018